ImpediMed Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

ImpediMed heeft een totaal eigen vermogen van A$40.7M en een totale schuld van A$0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk A$47.0M en A$6.2M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

AU$0

Schuld

Rente dekkingsratio	n/a
Contant	AU$24.63m
Aandelen	AU$40.74m
Totaal verplichtingen	AU$6.24m
Totaal activa	AU$46.99m

Recente financiële gezondheidsupdates

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Sep 28

Recent updates

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

Jun 26

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Mar 05

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Nov 23

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

Jul 11

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

Mar 27

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Sep 28

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

Jun 10

A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)

Feb 01

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$29.5M ) IPD } overtreffen de korte termijn passiva ( A$4.7M ).

Langlopende schulden: De kortetermijnactiva IPD ( A$29.5M ) overtreffen de langetermijnschulden ( A$1.6M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: IPD is schuldenvrij.

Schuld verminderen: IPD heeft de afgelopen 5 jaar geen schulden gehad.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: IPD heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: IPD heeft voldoende kasruimte voor 1.4 jaar als de vrije kasstroom blijft groeien met een historisch percentage van 1.3 % per jaar.

ImpediMed Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Recent updates

ImpediMed Limited to Report Q1, 2025 Results on Oct 22, 2024

ImpediMed Limited, Annual General Meeting, Nov 19, 2024

Price target decreased by 8.8% to AU$0.15

Consensus revenue estimates decrease by 14%

Board Member recently bought AU$73k worth of stock

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2027

ImpediMed Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Forecast to breakeven in 2026

ImpediMed Limited Appoints Parmjot Bains as CEO on an ongoing basis

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director

New minor risk - Market cap size

Independent Non-Executive Director recently bought AU$50k worth of stock

ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024

Price target decreased by 9.6% to AU$0.18

ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Independent Non-Executive Director recently bought AU$100k worth of stock

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates decrease by 13%

Independent Non-Executive Director recently bought AU$90k worth of stock

Price target decreased by 12% to AU$0.19

No longer forecast to breakeven

High number of new and inexperienced directors

New minor risk - Share price stability

ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024

Independent Non-Executive Director recently bought AU$135k worth of stock

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Consensus revenue estimates decrease by 20%

ImpediMed Limited Announces CFO Changes

Price target decreased by 16% to AU$0.23

Price target increased by 21% to AU$0.27

ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023

ImpediMed Limited, Annual General Meeting, Nov 30, 2023

High number of new directors

ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer

Consensus revenue estimates decrease by 23%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

ImpediMed Limited, Annual General Meeting, Sep 28, 2023

Price target increased by 27% to AU$0.21

ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

ImpediMed Limited Appoints Daniel Sharp as Director

Executive Director recently bought AU$144k worth of stock

Independent Non-Executive Chairman recently bought AU$82k worth of stock

No longer forecast to breakeven

MD, CEO & Director recently bought AU$52k worth of stock

MD, CEO & Director recently bought AU$54k worth of stock

Price target increased by 25% to AU$0.18

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

MD, CEO & Director recently bought AU$64k worth of stock

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)

Price target decreased by 7.7% to AU$0.17

ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023

ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival

Impedimed Limited Announces CEO Changes

ImpediMed Limited Announces Management Changes

Less than half of directors are independent

Executive Director & Interim CEO recently bought AU$164k worth of stock

Less than half of directors are independent

ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema

ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022

ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer

ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Consensus forecasts updated

Price target decreased to AU$0.18

ImpediMed Limited Announces Board Changes